Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Inflammatory Bowel Diseases 1Crohn Disease 1Colitis, Ulcerative 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

Blood Specimen Collection 3Infliximab 2Biopsy 2purine 1fumaric acid 1Tumor Necrosis Factor Inhibitors 1Thrombin Time 1Surveys and Questionnaires 1Sulfasalazine 1Standard of Care 1Single-Balloon Enteroscopy 1Registries 1Proctocolectomy, Restorative 1Practice Guidelines as Topic 1Phlebotomy 1Methotrexate 1Methods 1Mesalamine 1Mercaptopurine 1Interviews as Topic 1Gastroscopy 1Etanercept 1Endoscopy 1Educational Status 1Early Intervention, Educational 1Dietary Fiber 1Diagnostic Imaging 1Colonoscopy 1CT-P13 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Inflammatory Bowel Diseases × CT-P13 × Clear all
NCT03452501 2021-02-23

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Hikma Pharmaceuticals LLC

Completed
157 enrolled

Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡